# Hemorrhagic Shock

Hemorrhagic shock demands immediate recognition, mechanical hemorrhage control, rapid blood-product delivery, and parallel definitive operative or endovascular management. This review emphasizes time-sensitive actions, reassessment, trauma-specific diagnostic limitations, and important evidence gaps in resuscitation targets and adjunctive pharmacotherapy.

**Clinical question:** How should physicians recognize and resuscitate hemorrhagic shock while expediting definitive hemorrhage control?

Updated: 2026-08-21T00:27:50.990603+00:00

## What matters in practice
- Treat suspected hemorrhagic shock as a time-critical hemorrhage-control emergency; clinical assessment, vital signs, shock index, end-tidal carbon dioxide, and point-of-care lactate may support recognition. [13]
- Control external bleeding immediately with pressure dressings, hemostatic wound packing, tourniquets, pelvic binders for suspected pelvic fracture, or junctional measures as anatomically appropriate. [13]
- Activate the institutional major hemorrhage protocol early and deliver initial blood components without delay; ACS Trauma Quality Improvement Program guidance cited in a registry analysis advises no more than 10 minutes from protocol activation to initial component delivery. [15]
- Reassess continuously during transfusion and pursue definitive operative or interventional radiology control in parallel; resuscitation cannot substitute for source control. [13][15]
- Traumatic brain injury complicates permissive-volume strategies because cerebral resuscitation prioritizes maintenance of adequate perfusion while hemorrhage resuscitation addresses intravascular volume loss. [24]

## Recognize hemorrhagic shock and act before confirmation

Diagnostic uncertainty should not delay hemorrhage control or resuscitation.

Hemorrhagic shock is primarily a clinical diagnosis in an actively bleeding patient. Use serial physiologic assessment rather than a single vital-sign snapshot: blood pressure, heart rate, shock index, end-tidal carbon dioxide when available, and point-of-care lactate are identified as useful components of prehospital recognition. [13]

Missed major hemorrhage has meaningful consequences. In a 947-patient prehospital study, major hemorrhage was missed in 41 of 138 patients; missed diagnosis was associated with a threefold higher mortality risk despite admission to a major trauma center. Penetrating mechanism and major abdominal injury independently increased the odds of a missed diagnosis. [12]

Perform resuscitation and localization simultaneously. Obtain large-bore intravenous access promptly; the prehospital blood transfusion guideline prefers intravenous access of 18-gauge or larger. [13]
- Escalate concern when mechanism, examination, or trajectory suggests concealed bleeding despite initially nondiagnostic physiology; penetrating injury and major abdominal injury are particularly vulnerable to underrecognition. [12]
- Use repeated bedside reassessment after each intervention rather than assuming that an initial response represents durable control. [13]

*Recognition features and immediate actions supported by available trauma literature. [12][13]*

| Finding or context | Clinical implication | Immediate action |
| --- | --- | --- |
| Abnormal vital signs, shock index, end-tidal carbon dioxide, or point-of-care lactate | Supports rapid recognition of life-threatening hemorrhagic shock but does not replace clinical judgment. [13] | Control hemorrhage, obtain vascular access, and activate escalation pathways. [13] |
| Penetrating mechanism or major abdominal injury | Associated with missed prehospital major hemorrhage. [12] | Maintain a low threshold for hemorrhage-focused evaluation and destination/trauma-team escalation. [12] |
| Diagnostic uncertainty with suspected active bleeding | Clinical diagnosis can be delayed; missed major hemorrhage is associated with increased mortality. [12] | Treat uncertainty as an indication for serial assessment and early resuscitative preparation. [12][13] |

## Control bleeding before physiology deteriorates further

Use anatomy-directed measures immediately while arranging definitive control.

For severe external wounds, use pressure dressings and wound packing, preferably with hemostatic products. Use tourniquets for substantial extremity hemorrhage; use wound packing or junctional tourniquets for junctional bleeding. Apply a pelvic binder when pelvic fracture is suspected. [13]

Definitive hemorrhage control must occur in parallel with component resuscitation. A registry-based analysis emphasizes that reducing time to definitive control is modifiable, while also cautioning that selected patients may require enough characterization of bleeding pathophysiology to guide the appropriate intervention. [15]
- Assign an explicit hemorrhage-control plan: external control, operative management, interventional radiology, or a combination. [13][15]
- Avoid allowing imaging or laboratory completion to become a substitute for timely source-control escalation in an unstable patient; the supplied evidence supports simultaneous life-saving interventions and timely transfusion. [15]

## Use early blood products and protocolized delivery

Resuscitate while controlling hemorrhage, with continuous response assessment.

Major hemorrhage protocols are intended to standardize rapid delivery of blood components and hemostasis-directed products during active resuscitation. In the cited trauma registry report, ACS Trauma Quality Improvement Program guidance advised a maximum 10-minute interval from major hemorrhage protocol activation to delivery of the initial blood components. [15]

Delay matters: in that registry analysis, each minute of delay to blood-component delivery was associated with higher odds of 30-day mortality (adjusted odds ratio 1.05; 95% CI, 1.01-1.09). This observational association supports operational urgency but does not establish a specific component ratio, volume target, or causally proven minute-by-minute effect. [15]

The 2025 prehospital clinical practice guideline supports early resuscitation with blood products for hemorrhagic shock regardless of etiology. Monitor response continuously during product administration; the guideline notes that reassessment of vital signs and clinical response can mitigate over-resuscitation from multiple prehospital units. [13][14]
- Activate the institutional major hemorrhage protocol early when ongoing bleeding and shock are suspected, rather than waiting for conventional laboratory confirmation. [15]
- Warm blood products and ensure warming-device calibration when used; the prehospital guideline includes warming equipment as a programmatic and operational consideration. [13]
- Use local massive-transfusion protocols for product selection, component sequence, coagulation testing, calcium replacement, and endpoint targets; these details are not specified in the supplied sources. [13][15]

### Fluids and vasoactive adjuncts

The available evidence does not support a universal crystalloid volume, blood-component ratio, blood-pressure target, or vasopressor regimen. A historical experimental report found that early Ringer lactate resuscitation after head injury with uncontrolled hemorrhagic shock worsened cerebral hemodynamics; this should be interpreted as mechanistic evidence rather than a current clinical protocol. [11]

In a randomized trial summarized in the search results, low-dose arginine vasopressin during trauma hemorrhagic-shock resuscitation reduced blood-product requirements. The available result does not provide a dose, eligibility criteria, mortality effect, or guideline endorsement; therefore, it should not displace blood-product resuscitation and hemorrhage control. [16]
- Do not infer a recommended vasopressin dose or routine indication from the supplied trial summary. [16]
- Do not use nitroglycerin in hemorrhagic shock; its labeling describes overdose hypotension as mediated by venodilation and arterial hypovolemia, requiring supportive volume restoration rather than a specific antidote. [4]

*Operational priorities in active hemorrhagic-shock resuscitation. [13][15]*

| Priority | Action | Monitoring or decision point |
| --- | --- | --- |
| Hemorrhage protocol | Activate early and target delivery of initial blood components within 10 minutes of activation, consistent with cited ACS TQIP guidance. [15] | Track activation-to-product time as a modifiable process measure. [15] |
| Blood-product administration | Begin early blood-product resuscitation while pursuing source control. [13][14] | Continuously reassess vital signs and clinical response to reduce risk of over-resuscitation. [13] |
| Definitive control | Coordinate operative and/or interventional radiology management in parallel with transfusion. [15] | Prioritize reduction in time to control while allowing selected diagnostic clarification when it changes the intervention. [15] |

## Use trajectory, not isolated measurements, to guide escalation

Persistent instability indicates ongoing bleeding or inadequate control until proved otherwise.

Continuously reassess physiologic response during blood-product administration. The prehospital guideline specifically emphasizes ongoing monitoring of response to blood products and repeated vital-sign assessment. [13]

A transient improvement after fluids or blood does not establish hemostasis. Escalate source-control efforts when instability recurs or fails to improve, and reassess for external, thoracic, abdominal, pelvic, junctional, or vascular bleeding based on mechanism and examination. The importance of timely definitive control is supported by trauma registry data. [13][15]

The supplied sources do not establish validated universal targets for shock index, lactate clearance, end-tidal carbon dioxide, blood pressure, hemoglobin, coagulation assays, or urine output in hemorrhagic shock. Use institution-specific trauma and massive-transfusion pathways for target-based monitoring.
- Document response after hemorrhage-control maneuvers and each blood-product interval. [13]
- Treat recurrent hemodynamic deterioration as a trigger for renewed search for ongoing hemorrhage and reassessment of the definitive-control plan. [13][15]

## Modify the resuscitation strategy when traumatic brain injury is present

Avoid treating traumatic brain injury and uncontrolled bleeding as interchangeable physiologic problems.

Concurrent traumatic brain injury creates a competing resuscitation priority. Hemorrhagic-shock resuscitation seeks restoration of lost blood volume, whereas traumatic brain injury management prioritizes maintenance of adequate cerebral perfusion. [24]

The supplied evidence does not define a specific blood-pressure target or fluid regimen for patients with combined traumatic brain injury and hemorrhagic shock. Early Ringer lactate resuscitation in an older experimental report worsened cerebral hemodynamics in head injury with uncontrolled hemorrhagic shock, reinforcing the need to avoid extrapolating simplified fluid strategies to this population. [11]
- In combined traumatic brain injury and hemorrhage, expedite hemorrhage control and coordinate trauma, anesthesia, and neurosurgical priorities; use current institutional neurotrauma protocols for perfusion targets.
- Do not apply permissive-volume or hypotension strategies without accounting for cerebral-perfusion risk; a precise threshold is not supported by the supplied sources. [11][24]

## Build a system that minimizes time to blood and control

Hemorrhagic-shock outcomes depend on coordinated operational performance.

Prehospital blood-transfusion programs require protocols for recognition, vascular access, transfusion procedure, adverse-reaction management, storage and transport, documentation, training, and quality review. The guideline recommends regular case review of prehospital transfusions, consideration of each transfusion as a sentinel event, outcome tracking, blood-product utilization analysis, and wastage monitoring. [13]

For receiving hospitals, measure activation-to-first-product time and time to definitive control. The cited registry study identifies blood-component delay as a potentially modifiable process associated with mortality, while recognizing confounding in observational estimates of timing and outcome. [15]
- Train teams to recognize hemorrhagic shock, perform hemorrhage-control adjuncts, administer blood products, and identify transfusion reactions. [13]
- Use case review to identify avoidable delays in recognition, protocol activation, product delivery, transfer, and source-control access. [13][15]

## Common questions

### When should a major hemorrhage protocol be activated?

Activate early when active bleeding with hemorrhagic shock is suspected. The supplied trauma evidence supports rapid standardized blood-component delivery and cites ACS TQIP guidance for initial components within 10 minutes of activation. [15]

### Which bedside findings are useful for recognizing hemorrhagic shock?

Clinical assessment remains central. Serial vital signs, shock index, end-tidal carbon dioxide, and point-of-care lactate may support recognition; none should delay hemorrhage control when suspicion is high. [13]

### What external hemorrhage-control adjuncts should be used?

Use pressure dressings and hemostatic wound packing for severe wounds, tourniquets for significant extremity bleeding, pelvic binders for suspected pelvic fractures, and wound packing or junctional tourniquets for junctional hemorrhage. [13]

### Is vasopressin standard therapy for traumatic hemorrhagic shock?

No routine role can be established from the supplied evidence. A trial summary reports lower blood-product requirements with low-dose arginine vasopressin, but provides no dose, mortality result, or guideline recommendation. [16]

## References
1. prescribing information - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020702Orig1s079correctedlbl.pdf
2. This label may not be the latest approved by FDA. For current ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021611s013s015lbl.pdf
3. [PDF] 3953322 1 This label may not be the latest approved by FDA. For ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020938s026lbl.pdf
4. highlights of prescribing information — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=58d78805-3e8c-4859-b2e0-e3089f925280&type=display
5. 2023 First Generic Drug Approvals | FDA — www.fda.gov — https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2023-first-generic-drug-approvals
6. https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/ ... — nctr-crs.fda.gov — https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/bfdfe235-d717-4855-a3c8-a13d26dadede/spl-doc
7. 1 This label may not be the latest approved by FDA. For ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214783s005lbl.pdf
8. These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION.
      
      
DEFERASIROX tablets for oral suspension
 
Initial U.S. Approval: 2005 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dc690f20-533e-490e-b13d-143382e02351&type=display
9. 2025 First Generic Drug Approvals — www.fda.gov — https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2025-first-generic-drug-approvals
10. DailyMed - EFFEXOR XR- venlafaxine hydrochloride capsule, extended release — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c848a5d8-ba94-4c84-80e3-0bf35fb8e32e
11. Delayed Fluid Resuscitation of Head Injury and ... — jamanetwork.com — https://jamanetwork.com/journals/jamasurgery/fullarticle/211566
12. Identification of major hemorrhage in trauma patients in the prehospital setting: diagnostic accuracy and impact on outcome | Trauma Surgery & Acute Care Open — tsaco.bmj.com — https://tsaco.bmj.com/content/9/1/e001214
13. Prehospital blood transfusion coalition clinical practice guideline for civilian emergency medical services | Trauma Surgery & Acute Care Open — tsaco.bmj.com — https://tsaco.bmj.com/content/10/3/e001931
14. Prehospital blood transfusion coalition clinical practice ... — tsaco.bmj.com — https://tsaco.bmj.com/content/tsaco/10/3/e001931.full.pdf
15. Timing and volume of transfusion for adult major trauma patients with hemorrhagic shock: a registry-based cohort study | Trauma Surgery & Acute Care Open — tsaco.bmj.com — https://tsaco.bmj.com/content/9/1/e001248
16. Effect of Low-Dose Supplementation of Arginine ... — jamanetwork.com — https://jamanetwork.com/journals/jamasurgery/fullarticle/2749069
17. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001309
18. Digital twin mathematical models suggest individualized hemorrhagic shock resuscitation strategies — www.nature.com — https://www.nature.com/articles/s43856-024-00535-6
19. Articles on hemorrhagic shock published between 2000 ... — www.cell.com — https://www.cell.com/heliyon/fulltext/S2405-8440(23)06048-6
20. Part 1: Executive Summary: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care | Circulation — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001372
21. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/ ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001415
22. Current Concepts on the Management of Shock | Circulation — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/01.CIR.16.6.1097
23. Hemodynamic Management in Trauma and Hemorrhagic ... — www.nature.com — https://www.nature.com/nature-index/topics/l4/hemodynamic-management-in-trauma-and-hemorrhagic-shock
24. Resuscitation from hemorrhagic shock after traumatic brain ... — www.nature.com — https://www.nature.com/articles/s41598-021-81717-3

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.